Head-To-Head Analysis: XTL Biopharmaceuticals (NASDAQ:XTLB) and TFF Pharmaceuticals (NASDAQ:TFFP)

XTL Biopharmaceuticals (NASDAQ:XTLB) and TFF Pharmaceuticals (NASDAQ:TFFP) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation.

Volatility and Risk

XTL Biopharmaceuticals has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500. Comparatively, TFF Pharmaceuticals has a beta of 2.47, indicating that its stock price is 147% more volatile than the S&P 500.

Valuation & Earnings

This table compares XTL Biopharmaceuticals and TFF Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
XTL Biopharmaceuticals N/A N/A -$1.35 million N/A N/A
TFF Pharmaceuticals N/A N/A -$11.87 million ($5.31) -3.18

Analyst Recommendations

This is a summary of current ratings and recommmendations for XTL Biopharmaceuticals and TFF Pharmaceuticals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
XTL Biopharmaceuticals 0 0 0 0 N/A
TFF Pharmaceuticals 0 0 4 0 3.00

TFF Pharmaceuticals has a consensus target price of $27.00, suggesting a potential upside of 59.86%. Given TFF Pharmaceuticals’ higher possible upside, analysts clearly believe TFF Pharmaceuticals is more favorable than XTL Biopharmaceuticals.

Insider and Institutional Ownership

8.6% of XTL Biopharmaceuticals shares are owned by institutional investors. Comparatively, 24.3% of TFF Pharmaceuticals shares are owned by institutional investors. 10.4% of TFF Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares XTL Biopharmaceuticals and TFF Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
XTL Biopharmaceuticals N/A -38.54% -37.40%
TFF Pharmaceuticals N/A -59.54% -57.08%

Summary

TFF Pharmaceuticals beats XTL Biopharmaceuticals on 5 of the 9 factors compared between the two stocks.

XTL Biopharmaceuticals Company Profile

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. XTL Biopharmaceuticals Ltd. has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was founded in 1993 and is headquartered in Ramat Gan, Israel.

TFF Pharmaceuticals Company Profile

TFF Pharmaceuticals, Inc., an early-stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing, or TFF, technology platform. It intends to initially focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company has a research collaboration with the University of Georgia's Center for Vaccines and Immunology (CVI), along with the University of Texas at Austin (UT Austin), to evaluate the immunogenicity of universal influenza vaccines; and cooperative research and development agreement with United States Army Medical Research Institute of Infectious Diseases for use of its thin film freezing technology platform. TFF Pharmaceuticals, Inc. also has a joint development and collaboration agreement with Augmenta Bioworks, Inc. to develop commercial products incorporating Augmenta's human-derived monoclonal antibodies for COVID-19 therapeutics. The company was founded in 2018 and is based in Austin, Texas.

Receive News & Ratings for XTL Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XTL Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.